All Stories

  1. Investigation of healthcare-associated COVID-19 in a large French hospital group by whole-genome sequencing
  2. Decrease of hospital- and community-acquired bloodstream infections due to Streptococcus pneumoniae and Streptococcus pyogenes during the first year of the COVID-19 pandemic: A time-series analysis in Paris region
  3. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019
  4. Early-onset neonatal sepsis in the Paris area: a population-based surveillance study from 2019 to 2021
  5. Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France
  6. Decrease of carbapenemase‐producing Enterobacteriaceae incidence during the first year of the COVID‐19 pandemic
  7. Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
  8. atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure
  9. Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020
  10. Clinical, epidemiological and therapeutic characteristics of Mycoplasma genitalium infection in a French STI center
  11. Surging bloodstream infections and antimicrobial resistance during the first wave of COVID–19: a study in a large multihospital institution in the Paris region
  12. Corynebacterium striatum thrombophlebitis: a nosocomial multidrug-resistant disease?
  13. A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples
  14. Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study
  15. Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections
  16. Impact of stewardship strategy on antibiotic use in Clostridoides difficile infection
  17. Controlling healthcare-associated transmission of SARS-CoV-2 variant of concern 202012/01 in a large hospital network
  18. Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay
  19. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
  20. Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis
  21. Impact of the revised definition of extensively drug-resistant tuberculosis
  22. Mycobacterium chimaera Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical Mycobacterium chimaera Infection Outbreak
  23. Efficacy of aztreonam with ß-lactamase inhibitors against metallo-carbapenemase-producing Enterobacteria
  24. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
  25. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study
  26. Do Contact Precautions Reduce the Incidence of Intensive Care Unit–Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P. aeruginosa) Cluster-Randomized Crossover Trial
  27. Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety
  28. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses
  29. Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema
  30. Usefulness of point-of-care multiplex PCR to rapidly identify pathogens responsible for ventilator-associated pneumonia and their resistance to antibiotics: an observational study
  31. Validation of the Bacterial Meningitis Score in adults consulting at an emergency department: a retrospective multicentric study
  32. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective
  33. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
  34. Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing
  35. Awareness among French healthcare workers of the transmission of multidrug resistant organisms: a large cross-sectional survey
  36. Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium
  37. A nationwide survey on involvement of clinical microbiologists in antibiotic stewardship programmes in large French hospitals
  38. Erwinia billingiaeas Unusual Cause of Septic Arthritis, France, 2017
  39. Trends and prediction of antimicrobial susceptibility in urinary bacteria isolated in European emergency departments: the EuroUTI 2010-2016 Study
  40. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
  41. Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012–2013 study
  42. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study
  43. Introduction – épidémiologie de la tuberculose et de l’infection tuberculeuse latente
  44. Recommandations pratiques pour l’utilisation et l’interprétation des tests de détection de l’interféron gamma dans le diagnostic de l’infection tuberculeuse latente et de la tuberculose maladie
  45. Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen
  46. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
  47. Trimethoprim susceptibility in E. coli community-acquired urinary tract infections in France
  48. Management and outcome of bloodstream infections: a prospective survey in 121 French hospitals (SPA-BACT survey)
  49. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016
  50. Bacillus cereus, a serious cause of nosocomial infections: Epidemiologic and genetic survey
  51. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study
  52. Comparison of methods available for identification of Mycobacterium chimaera
  53. Surveillance for control of antimicrobial resistance
  54. Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015
  55. Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia
  56. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study
  57. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
  58. Xe Congrès international de la Société de pathologie exotique, 8-9 novembre 2017, Haïphong (Vietnam) – Accès à la chirurgie en zones tropicales
  59. Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis
  60. Erratum to ‘Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum β-lactamase-producing Enterobacteriaceae’ [International Journal of Antimicrobial Agents 49/1 67–73]
  61. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria
  62. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries
  63. Multidrug and extensively drug-resistant tuberculosis
  64. Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory
  65. Application of guidelines for aminoglycosides use in French hospitals in 2013–2014
  66. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors
  67. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
  68. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice
  69. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
  70. In vivo Mycobacterium tuberculosisfluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests
  71. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
  72. MYCOBACT-16 - Tolérance et efficacité d’un traitement prolongé avec bédaquiline dans la tuberculose multi résistante
  73. Performance of the New Version (v2.0) of the GenoType MTBDRslTest for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains
  74. Multidrug-resistant bacteria transmitted through high-density EEG in ICU
  75. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis
  76. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013
  77. XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions
  78. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis
  79. qnrA6genetic environment and quinolone resistance conferred onProteus mirabilis
  80. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial
  81. Carbapenem use in French hospitals: A nationwide survey at the patient level
  82. Antibiotic use and good practice in 314 French hospitals: The 2010 SPA2 prevalence study
  83. Corrigendum to ‘Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams’ [Clin Microbiol Infec 21 (2015) 649.e1–649.e10]
  84. High Rate of Multidrug-Resistant Gram-Negative Bacilli Carriage and Infection in Hospitalized Returning Travelers: a Cross-Sectional Cohort Study
  85. Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex
  86. First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs
  87. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis
  88. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams
  89. Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux
  90. Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: room for improvement
  91. Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011
  92. Survey of French physician practices in treatment and control of transmission of smear-positive tuberculosis
  93. Registre électronique pour la prise en charge, le suivi et la surveillance des cas de tuberculose à bacilles multi-résistants en France
  94. « Groupe thérapeutique des infections à mycobactéries difficiles à traiter » et prise en charge des TB MDR : bilan 2005–2013
  95. Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis
  96. Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France
  97. Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort
  98. Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare
  99. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis
  100. Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12
  101. K-06: Évaluation de nouveaux traitements oraux intermittents dans un modèle murin d’infection à Mycobacterium ulcerans
  102. Chirurgie et tuberculose multi/ultrarésistante : une revue de la littérature réhabilite une intervention adjuvante à l’antibiothérapie chez des patients sélectionnés
  103. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012
  104. Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility
  105. First report of the predominance of clonal complex 398 Staphylococcus aureus strains in osteomyelitis complicating diabetic foot ulcers: a national French study
  106. Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis
  107. Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007
  108. Different Factors Associated with CTX-M-Producing ST131 and Non-ST131 Escherichia coli Clinical Isolates
  109. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union
  110. Assessment of Organizational Measures to Prevent Nosocomial Tuberculosis in Health Facilities of 4 Sub-Saharan Countries in 2010
  111. Aerosolized Antibiotics for Ventilator-associated Pneumonia
  112. Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa  and Acinetobacter baumannii 
  113. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
  114. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis
  115. Alliance contre les bactéries multirésistantes : sauvons les antibiotiques !
  116. Link Between Carbapenemase‐ProducingEnterobacteriaCarriage and Cross‐Border Exchanges: Eight‐Year Surveillance in a Large French Multihospitals Institution
  117. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients
  118. Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France
  119. Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris
  120. Distinguishing Colonization From Infection With Staphylococcus aureus in Diabetic Foot Ulcers With Miniaturized Oligonucleotide Arrays: A French multicenter study
  121. Patient's Origin and Lifestyle Associated with CTX-M-Producing Escherichia coli: A Case-Control-Control Study
  122. Point prevalence survey of antibiotic use in French hospitals in 2009
  123. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE)
  124. Multidrug‐ResistantAcinetobacter baumanniiInfections in Three Returning Travelers Evacuated From Algeria, Thailand, and Turkey After Hospitalization in Local Intensive Care Units
  125. Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused byPseudomonas aeruginosa
  126. Halte à la résistance : sauvons les antibiotiques
  127. Low carriage of vancomycin-resistant enterococci in the digestive tract of French hospitalised patients: a nationwide prospective study in 2006
  128. Comparison of Nine Phenotypic Methods for Detection of Extended-Spectrum  -Lactamase Production by Enterobacteriaceae
  129. Panton-Valentine Leukocidin-Positive and Toxic Shock Syndrome Toxin 1-Positive Methicillin-ResistantStaphylococcus aureus: a French Multicenter Prospective Study in 2008
  130. Résistance aux antituberculeux et impasse thérapeutique
  131. Nationwide Investigation of Extended-Spectrum β-Lactamases, Metallo-β-Lactamases, and Extended-Spectrum Oxacillinases Produced by Ceftazidime-Resistant Pseudomonas aeruginosa Strains in France
  132. Curbing Methicillin-Resistant Staphylococcus aureus in 38 French Hospitals Through a 15-Year Institutional Control Program
  133. Effect of Catheter-Lock Solutions on Catheter-Related Infection and Inflammatory Syndrome in Hemodialysis Patients: Heparin versus Citrate 46% versus Heparin/Gentamicin
  134. Rapid Curbing of a Vancomycin-ResistantEnterococcus faeciumOutbreak in a Nephrology Department
  135. Carriage of Methicillin-Resistant Staphylococcus aureus in Home Care Settings
  136. Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice
  137. Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting
  138. Systematic Microbiological Tests in Kidney Transplantation and Their Value in Predicting Posttransplantation Infection
  139. Increase in hospital-acquired bloodstream infections caused by extended spectrum β-lactamase-producing Escherichia coli in a large French teaching hospital
  140. La résistance aux antituberculeux en France à travers les données des réseaux Azay-Mycobactéries et du Centre National de Référence des Mycobactéries
  141. Entérocoques résistants à la vancomycine : données des réseaux de l’ONERBA et résultats de l’enquête nationale trans-réseaux 2006 sur le portage digestif
  142. Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice
  143. Extended-spectrum β-lactamases in long-term-care facilities
  144. Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004
  145. A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995 2004
  146. Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice
  147. Preemptive Isolation to Prevent Methicillin-Resistant Staphylococcus aureus Cross-Transmission in Diabetic Foot
  148. An intervention programme for the management of multidrug-resistant tuberculosis in France
  149. Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene
  150. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients*
  151. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis
  152. An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001–2002
  153. Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin
  154. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002–2005
  155. Gentamicin-Susceptible or Gentamicin-Resistant Methicillin-ResistantStaphylococcus aureusA Case-Case Study
  156. In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans
  157. Implementation of isolation precautions: role of a targeted information flyer
  158. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983–2002
  159. Modification des caractéristiques épidémiologiques de la tuberculose multirésistante en France en 2002-2003
  160. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease
  161. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital
  162. Résistance aux antituberculeux
  163. Methicillin-resistant Staphylococcus aureus producing Panton–Valentine leukocidin in a retrospective case series from 12 French hospital laboratories, 2000–2003
  164. Résistance aux antibiotiques : des Chiffres de l'ONERBA au Bon Usage
  165. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains
  166. Nosocomial infections and hospital mortality: a multicentre epidemiological study
  167. A-04 Incidence et caractéristiques de la méningite tuberculeuse en France en 2000
  168. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact
  169. Preventing Central Venous Catheter-Associated Primary Bloodstream Infections: Characteristics of Practices Among Hospitals Participating in the Evaluation of Processes and Indicators in Infection Control (EPIC) Study
  170. Multidrug-resistant tuberculosis: eight years of surveillance in France
  171. Comparison of US and non-US central venous catheter infection rates: Evaluation of processes and indicators in infection control study
  172. La multirésistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992
  173. Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice
  174. Sixty-three Cases of Mycobacterium marinum Infection
  175. Lung Tissue Concentrations of Nebulized Amikacin during Mechanical Ventilation in Piglets with Healthy Lungs
  176. Évolution de la sensibilité aux quinolones et aux fluoroquinolones des bacilles à Gram négatif aérobies isolés dans un hôpital universitaire (1992–2000)
  177. Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice
  178. Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice
  179. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98
  180. Outcomes of Primary and Catheter-related Bacteremia
  181. Global Trends in Resistance to Antituberculosis Drugs
  182. Impact of Hospital Care on Incidence of Bloodstream Infection: The Evaluation of Processes and Indicators in Infection Control Study
  183. Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice
  184. The Influence of the Composition of the Nursing Staff on Primary Bloodstream Infection Rates in a Surgical Intensive Care Unit
  185. Outcome of Multi-drug-resistant Tuberculosis in France
  186. Type II Topoisomerase Mutations in Ciprofloxacin-Resistant Strains of Pseudomonas aeruginosa
  187. Pacemaker Endocarditis Due to Candida albicans: Case Report and Review
  188. Pharmacodynamics of antibiotics in fibrin clots
  189. Reexpansion Pulmonary Edema Localized to a Lobe